Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism 4-1BBL inhibitors(Tumor necrosis factor ligand superfamily member 9 inhibitors), PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Discovery | KR | 15 Aug 2024 |